Add Formweb to your mobile device
System Formulary Update
Breztri Aerosphere Therapeutic Interchange
Situation
Budesonide 160 mcg-glycopyrrolate 9 mcg-formoterol fumarate 4.8 mcg (Breztri Aerosphere) is a non-formulary inhaled corticosteroid and long-acting beta agonist combination inhaler indicated for chronic obstructive pulmonary disease maintenance treatement. An evaluation of a therapeutic interchange to formulary equivalents is needed.
Background
System Formulary P&T Subcommittee and System P&T Committee voted to standardize the inhaled corticosteroids (ICS) and ICS-long-acting beta agonist (ICS-LABA) combinations class in January 2020. However, Breztri Aerosphere was not accounted for in the original class review as it was approved in July 2020.
Assessment
A therapeutic interchange for Breztri Aerosphere 160 mcg-9 mcg-4.8 mcg built into Epic may improve workflow when converting patients to formulary products at admission.
Recommendation
|
Non-Formulary Order |
ADULTS - Formulary Equivalent Order |
PEDIATRICS - Formulary Equivalent Order |
|
Budesonide/Glycopyrrolate/Formoterol Fumarate (Breztri Aerosphere) 160-9-4.8 mcg/dose Inhaler 2 inhalations twice daily |
Fluticasone/Vilanterol (Breo Ellipta) 200-25 mcg/dose Inhaler 1 inhalation daily Umeclidinium (Incruse Ellipta) 62.5 mcg/dose Inhaler 1 inhalation daily |
Not applicable |